Home › Opioid Overdose › NCT07787039

Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 Phase

Empowering Support Persons to Enhance the Recovery Capital of Postpartum Women With Opioid Use Disorder - R61 Phase

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* must be biological females
* must be currently within 6 weeks postpartum
* must be able to read, write, and speak English at a 6th-grade level
* must be diagnosed and receiving treatment for, or willing to receive treatment for opioid use disorder at the PROUD clinic
* must identify a support person who also consents to participate. Patient participants must identify prospective support persons in order to complete consent

Exclusion Criteria:

* pregnancy
* planned discharge to a long-term inpatient care facility (e.g., hospice)
* hospitalization for a suicide attempt
* major mental health disorder that requires treatment before OAT can be considered
* stillbirth or neonatal death of the index pregnancy/infant, as determined from the obstetric record.

About the study

We are studying whether training an identified support person and providing patient navigation (i.e. a peer recovery specialist assisting you with finding the right support) after delivery can increase "recovery capital"-the resources that help people with opioid use disorder (OUD) stay in treatment and recover. This study will build upon the research team's prior work in conducting research among pregnant and parenting women with OUD. This project will be directed by the research team at Friends Research Institute in close collaboration with their research and clinical partners at the University of Pennsylvania in Philadelphia, PA. A two-phase study is proposed with an initial 1-year developmental phase (R61) that will develop and pilot test STORC to include support person training. A second 4-year phase (R33) will test STORC in a parallel, two-arm, randomized controlled trial design at two study sites.

What is being tested

• STORC (behavioral)

Sponsor: Friends Research Institute, Inc. · Participants: 10 · Started: Sep 26, 2026

Contact the study team

• Karen Alexander, PhD · Phone: 9084510141
• Rachel Woolworth, MSW · Phone: 267-258-2067

Official record on ClinicalTrials.gov — NCT07787039

Locations in the U.S.

Conditions

• Opioid Overdose

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.